In certain tumor types, the loss of p53 function is associated with chemoresistance, and cancers with p53 mutations generally respond poorly to therapeutics [157], thereby prompting the investigation of anticancer agents that act independently of p53 status. This evidence concerns the gene TP53 and neoplasm.